ATE510562T1 - Anti-ailim antikörper zur behandlung von crohn's - Google Patents
Anti-ailim antikörper zur behandlung von crohn'sInfo
- Publication number
- ATE510562T1 ATE510562T1 AT02712418T AT02712418T ATE510562T1 AT E510562 T1 ATE510562 T1 AT E510562T1 AT 02712418 T AT02712418 T AT 02712418T AT 02712418 T AT02712418 T AT 02712418T AT E510562 T1 ATE510562 T1 AT E510562T1
- Authority
- AT
- Austria
- Prior art keywords
- crohn
- treatment
- ailim
- inflammatory bowel
- bowel diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001089158 | 2001-03-27 | ||
| JP2002019291A JP4210454B2 (ja) | 2001-03-27 | 2002-01-29 | 炎症性腸疾患治療剤 |
| PCT/JP2002/001361 WO2002076504A1 (en) | 2001-03-27 | 2002-02-18 | Remedies for inflammatory bowel diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE510562T1 true ATE510562T1 (de) | 2011-06-15 |
Family
ID=26612136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02712418T ATE510562T1 (de) | 2001-03-27 | 2002-02-18 | Anti-ailim antikörper zur behandlung von crohn's |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7465444B2 (de) |
| EP (1) | EP1374902B1 (de) |
| JP (1) | JP4210454B2 (de) |
| KR (1) | KR100602940B1 (de) |
| CN (1) | CN1291757C (de) |
| AT (1) | ATE510562T1 (de) |
| AU (1) | AU2002232222B8 (de) |
| BR (1) | BR0208446A (de) |
| CA (1) | CA2441577C (de) |
| CZ (1) | CZ20032692A3 (de) |
| HU (1) | HU229378B1 (de) |
| IL (2) | IL158088A0 (de) |
| MX (1) | MXPA03008760A (de) |
| NO (1) | NO332316B1 (de) |
| NZ (1) | NZ528554A (de) |
| RU (1) | RU2281118C2 (de) |
| SK (1) | SK288036B6 (de) |
| WO (1) | WO2002076504A1 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| EP1601682B1 (de) * | 2003-03-12 | 2008-05-07 | Rappaport Family Institute For Research in the Medical Sciences | Verbindungen und verfahren zur diagnose von prostatakrebs |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| EP1740617B1 (de) * | 2004-04-23 | 2013-10-16 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | Verfahren zur behandlung von erkrankungen, die mit t-zellen im zusammenhang stehen, durch eliminierung von icos-positiven zellen in vivo |
| AU2013203437A1 (en) * | 2005-07-18 | 2013-05-02 | Amgen Inc. | Human anti-B7RP1 neutralizing antibodies |
| SG196835A1 (en) * | 2005-07-18 | 2014-02-13 | Amgen Inc | Human anti-b7rp1 neutralizing antibodies |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| SI3121280T1 (sl) * | 2008-11-13 | 2025-08-29 | Nogra Pharma Limited | Antismiselne sestave in postopki za njihovo izdelavo ter uporabo |
| US9376493B2 (en) * | 2011-03-31 | 2016-06-28 | INSERM (Institut National de la Sante et de la Recherche Mediacale) | Antibodies directed against ICOS and uses thereof |
| CA2841416A1 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| MD480Z (ro) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Metoda de tratament al colitei ulceroase nespecifice acute |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| HRP20201113T1 (hr) | 2013-03-15 | 2020-10-30 | Glaxosmithkline Intellectual Property Development Limited | Vežući proteini protiv lag-3 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| RU2021133819A (ru) | 2015-09-02 | 2021-12-10 | Иммутеп С.A.С. | Анти-lag-3 антитела |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| SG11201809560QA (en) | 2016-05-05 | 2018-11-29 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
| WO2018015879A1 (en) | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| WO2018225034A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| EP3635011A1 (de) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationstherapie mit icos-agonist und ox40-agonisten zur behandlung von krebs |
| CA3066048A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| WO2019053613A2 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| EP3692033A1 (de) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulatoren des stimulators von interferongenen (sting) zur verwendung bei der behandlung von hiv |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN112469416A (zh) | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用于治疗癌症的ii型蛋白质精氨酸甲基转移酶抑制剂和icos结合蛋白的组合 |
| CN112469441A (zh) | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| CA3117746A1 (en) | 2018-10-22 | 2020-04-30 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
| EP3962493A2 (de) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Verfahren zur modulation der immunreaktivität/konzentration von irf oder sting oder zur behandlung von krebs mit der verabreichung eines sting-modulators und/oder eines purinergischen rezeptormodulators oder eines postzellularen signalisierungsfaktors |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| EP4034562B1 (de) | 2019-09-27 | 2025-10-29 | GlaxoSmithKline Intellectual Property Development Limited | Antigen bindende proteine |
| EP4076434A1 (de) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Kombination von antikrebstherapien mit induktoren der eisenabhängigen zellulären zerlegung |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| CA3171557A1 (en) | 2020-04-14 | 2021-10-21 | Marc S. BALLAS | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
| AU2021257570A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN116917273A (zh) | 2021-03-02 | 2023-10-20 | 葛兰素史克知识产权发展有限公司 | 作为dnmt1抑制剂的经取代的吡啶 |
| CA3208203A1 (en) * | 2021-03-12 | 2022-09-15 | Harlan S. Robins | Crohn's disease-associated t cell receptor-related methods |
| US20240166747A1 (en) | 2021-03-31 | 2024-05-23 | Glazosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| EP4363059A1 (de) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Zur förderung der apo-übertragung manipulierte immunzellen und verwendungen davon |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| EP4598946A1 (de) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Für trif und zusätzliche polypeptide codierende nukleinsäuremoleküle und deren verwendung bei der behandlung von krebs |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
| US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| RU2089179C1 (ru) * | 1995-12-14 | 1997-09-10 | Закрытое акционерное общество "ВАМ" | Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования |
| JP4864175B2 (ja) | 1996-01-23 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 発作に関する抗―ｃｄ１８抗体 |
| US5914112A (en) | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| BR9711499A (pt) | 1996-09-18 | 1999-08-24 | Zetesis Spa | Uso de prote¡nas como agentes contra doen-as auto-imunes |
| EP1878748A2 (de) | 1996-11-08 | 2008-01-16 | Biogen Idec Inc. | Identifikation der Wechselwirkungen einzelner Bindungen zwischen gewissen Antikörpern und humanen kostimulierenden B7.1- und B7.2-Antigenen |
| WO1998037415A1 (en) | 1997-02-20 | 1998-08-27 | The Regents Of The University Of California | ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| WO2001032675A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| JP4463418B2 (ja) | 1997-09-23 | 2010-05-19 | ドイツ連邦共和国 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| JPH11228442A (ja) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
| AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| JP2000154151A (ja) * | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
| CA2346496A1 (en) | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
| US6658450B1 (en) * | 1999-01-29 | 2003-12-02 | Avaya Technology Corp. | Method and system for memory resident transient storage of data associated with a plurality of collaborating computer processes |
| WO2000046240A2 (en) * | 1999-02-03 | 2000-08-10 | Amgen Inc. | Polypeptides involved in immune response |
| US7708993B2 (en) * | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| IL146106A0 (en) | 1999-05-06 | 2002-07-25 | Genetics Inst | Use of soluble costimulatory molecules to enhance immune responses |
| WO2001008700A1 (en) | 1999-07-28 | 2001-02-08 | Genetics Institute, Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
| WO2001012658A2 (en) * | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) * | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| AU7099200A (en) | 1999-09-03 | 2001-04-10 | Human Genome Sciences, Inc. | 52 human secreted proteins |
| EP1218504B1 (de) | 1999-09-21 | 2007-07-11 | Genetics Institute, LLC | Gl50 moleküle, sowie verwendungen derselben |
| AU2001245396A1 (en) | 2000-03-02 | 2001-09-12 | Mayo Foundation For Medical Education And Research | Hb7-h2, a novel co-stimulatory molecule |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| AU2002217969B2 (en) | 2000-11-28 | 2007-12-20 | Amgen Canada Inc. | Polypeptides involved in immune response |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US7428905B2 (en) * | 2004-07-30 | 2008-09-30 | R.J. Reynolds Tobacco Company | Method of making smokeable tobacco substitute filler having an increased fill value |
-
2002
- 2002-01-29 JP JP2002019291A patent/JP4210454B2/ja not_active Expired - Fee Related
- 2002-02-18 SK SK1330-2003A patent/SK288036B6/sk not_active IP Right Cessation
- 2002-02-18 AU AU2002232222A patent/AU2002232222B8/en not_active Ceased
- 2002-02-18 CN CNB028107470A patent/CN1291757C/zh not_active Expired - Fee Related
- 2002-02-18 IL IL15808802A patent/IL158088A0/xx unknown
- 2002-02-18 CA CA2441577A patent/CA2441577C/en not_active Expired - Fee Related
- 2002-02-18 CZ CZ20032692A patent/CZ20032692A3/cs unknown
- 2002-02-18 US US10/472,743 patent/US7465444B2/en not_active Expired - Fee Related
- 2002-02-18 RU RU2003131330/15A patent/RU2281118C2/ru active
- 2002-02-18 AT AT02712418T patent/ATE510562T1/de not_active IP Right Cessation
- 2002-02-18 EP EP02712418A patent/EP1374902B1/de not_active Expired - Lifetime
- 2002-02-18 KR KR1020037012380A patent/KR100602940B1/ko not_active Expired - Fee Related
- 2002-02-18 HU HU0303622A patent/HU229378B1/hu not_active IP Right Cessation
- 2002-02-18 NZ NZ528554A patent/NZ528554A/en not_active IP Right Cessation
- 2002-02-18 BR BR0208446-5A patent/BR0208446A/pt not_active Application Discontinuation
- 2002-02-18 MX MXPA03008760A patent/MXPA03008760A/es active IP Right Grant
- 2002-02-18 WO PCT/JP2002/001361 patent/WO2002076504A1/ja not_active Ceased
-
2003
- 2003-09-24 IL IL158088A patent/IL158088A/en not_active IP Right Cessation
- 2003-09-26 NO NO20034312A patent/NO332316B1/no not_active IP Right Cessation
-
2008
- 2008-11-11 US US12/268,882 patent/US8052972B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE510562T1 (de) | Anti-ailim antikörper zur behandlung von crohn's | |
| ATE315938T1 (de) | 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| GB0225475D0 (en) | Therapeutic agents | |
| GB0318447D0 (en) | Therapeutic agents | |
| FR10C0016I2 (fr) | Procedes et compositions s'appliquant au traitement de la glomerulonephrite | |
| DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| EP1499333A4 (de) | Verfahren zur behandlung von ileus | |
| DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| DE60144514D1 (de) | Verwendung von il-18 inhibitoren | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
| EP1416964A4 (de) | Behandlung und prävention von kanzerösen und präkanzerösen zuständen von leber, lunge und ösophagus | |
| MY139368A (en) | Novel cyclohexyl sulphones | |
| DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| ES2159287T3 (es) | Peptidos hemorreguladores. | |
| MXPA04001986A (es) | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |